Health Disparities and SARS-COV-2 Evolution: A Focused Viral Genomics Study

健康差异和 SARS-COV-2 进化：一项重点病毒基因组学研究

基本信息

批准号：
10381371
负责人：
JOHN P. KIRWAN
金额：
$ 73.76万
依托单位：
LSU PENNINGTON BIOMEDICAL RESEARCH CTR
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-08-15 至 2022-08-04
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10381371
关键词：
2019-nCoV Address Adherence Amino Acids Antibodies Antiviral Agents Area Awareness Bioinformatics Biological Body mass index CLIA certified COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 surveillance COVID-19 vaccine Cerebrovascular Disorders Chronic Chronic Disease Chronic Kidney Failure Classification Scheme Clinical Clinical Data Communities Community Health Education Community Outreach Data Data Analytics Diabetes Mellitus Diffusion Drops Evolution Gender Genetic Genetic Variation Healthcare Systems Human Hypertension Immune system Immunity Immunosuppressive Agents Impairment Individual Infection Information Dissemination Institution Knowledge Laboratories Length of Stay Lifting Linguistics Louisiana Malignant Neoplasms Methods Minority Molecular Epidemiology Monoclonal Antibodies Mutation Obesity Outcome Participant Pathogenicity Patients Pattern Phylogenetic Analysis Population Population Sizes Preventive measure Probability Process Renal dialysis Reporting Resource Informatics SARS-CoV-2 genome SARS-CoV-2 variant Severities Symptoms Testing Time Transplant Recipients Underinsured Underserved Population Uninsured Vaccinated Vaccination Vaccines Variant Viral Viral Drug Resistance Viral Genome Virus Vulnerable Populations age group base biomedical informatics clinical phenotype community engagement comorbidity design epidemiologic data health disparity immune clearance immunogenic immunogenicity improved innovation models and simulation next generation sequencing outreach pandemic disease pressure programs racial and ethnic sequencing platform study population trend variants of concern viral genomics virus genetics

项目摘要

Health Disparities and SARS-CoV-2 Evolution: A Focused Viral Genomics Study Project Summary/Abstract We hypothesize that prolonged COVID19 illness, re-infection, and/or post-vaccine infection in patients with chronic conditions are associated with specific SARS-CoV-2 lineages or mutations, and that increasing the awareness of the potential danger posed by variants of concern will improve testing adherence and variant tracking. We propose to use our established FDA- authorized COVID19 sequencing platform in combination with innovative data analytics and clinical bioinformatics as well as our BMI and community engagement KCAs. Our proposal addresses four of the priority areas indicated by NOT-GM-21-031, specifically: • Are there different variants present in the study population, and how has the number of cases caused by different variants changed over time in the study population? • How are different variants distributed among different racial, ethnical, gender, and/or age groups? • Are specific variants associated with different levels of manifestation of COVID19 symptoms? • Do vaccinated study participants still acquire the SARS-CoV-2 virus, and if so, what variants do they carry? We propose these Specific Aims: Specific Aim 1. To improve surveillance of COVID19 by integrating SARS-CoV-2 sequencing and clinical data with a focus on under-represented, vulnerable and remote populations. Using highly automated processes, we will identify variants/mutations associated with clinical phenotypes, including prolonged asymptomatic/antibody-positive individuals, re-infected, and vaccinated populations. All trend data will be integrated in the AWS cloud where it can be accessed by relevant stakeholders including testing and vaccine program partners. Specific Aim 2. To develop and validate simulation models that incorporate SARS-CoV-2 genetic data with clinical outcomes to predict COVID19 case severity in Louisiana by region as vaccination levels increase. Specific Aim 3. To design and deploy culturally and linguistically appropriate outreach material on SARS-CoV-2 and determine whether increased knowledge of the potential danger of adaptive mutations improves acceptance of testing and vaccination.

健康差异和 SARS-CoV-2 进化：一项重点病毒基因组学研究项目概要/摘要我们目睹了新冠肺炎 (COVID19) 疾病的长期患病、再次感染和/或疫苗后感染慢性病患者与特定的 SARS-CoV-2 谱系或突变有关，提高对所关注的变种所构成的潜在危险的认识将我们建议使用我们既定的 FDA- 来提高测试依从性和变异跟踪。授权的 COVID19 测序平台结合创新的数据分析和临床生物信息学以及我们的 BMI 和社区参与 KCA 我们的建议。解决 NOT-GM-21-031 指出的四个优先领域，具体来说： • 研究人群中是否存在不同的变异，病例数量如何？是由研究人群中随时间变化的不同变异引起的？ • 不同变异在不同种族、民族、性别和/或年龄之间的分布情况如何团体？ • 特定变异是否与不同程度的新冠肺炎症状表现相关？ • 疫苗研究参与者是否仍会感染 SARS-CoV-2 病毒？如果是，有哪些变种他们携带吗？我们提出以下具体目标：具体目标 1. 通过整合 SARS-CoV-2 测序和重点关注代表性不足、弱势和偏远人群的临床数据。自动化流程，我们将识别与临床表型相关的变异/突变，包括长期无症状/抗体阳性个体、再次感染和肺炎所有趋势数据都将集成到 AWS 云中，可供用户访问。相关利益攸关方，包括检测和疫苗计划合作伙伴。具体目标 2. 开发并验证包含 SARS-CoV-2 遗传信息的模拟模型用于预测路易斯安那州各地区 COVID19 病例严重程度的临床结果数据：疫苗接种水平提高。具体目标 3. 设计和部署适合文化和语言的宣传材料 SARS-CoV-2 并确定是否增加了对适应潜在危险的认识突变提高了检测和疫苗接种的接受度。